The p53 tumor suppressor protein plays an important role in preventing cancer development by arresting or killing potential tumor cells. Downregulated p53 levels, or mutations within the p53 gene, leading to the loss of p53 activity, are found in many breast carcinomas. Here we demonstrate that the p53 gene is transcriptionally upregulated in the normal mouse mammary gland at midpregnancy. We show that the specific isoform nuclear factor 1-C2 (NF1-C2) plays an important role in this activation. Functional mutation of the NF1-binding site in the mouse p53 promoter resulted in a reduction of the gene expression to less than 30% in mammary epithelial cells. By the use of two powerful techniques, chromatin immunoprecipitation and oligonucleotide decoy, we verify the importance of NF1-C2 in p53 gene activation in vivo. These findings demonstrate a broader role for NF1-C2 in the mammary gland at midpregnancy, beyond its earlier reported activation of milk protein genes. We also demonstrate that NF1-A1 proteins are produced in the mouse mammary gland. However, due to their lower affinity to the NF1-binding site, these proteins are not involved in the transcriptional upregulation of p53 at midpregnancy. This paper constitutes the first report demonstrating the importance of NF1 proteins in the p53 gene activation in the mouse mammary gland. It is also the first time that p53 gene activation is coupled to a specific, endogenously expressed NF1 isoform.
Introduction
The mammary gland is one of the few tissues that undergo repeated cycles of development and regression in the adult animal. The development and control of the mammary gland proceed in distinct stages, which are correlated to the actual hormonal status. The fully developed gland consists of alveolar epithelial cells, which sequentially synthesize milk proteins during the second half of pregnancy. During its developmental cycle, the mammary gland displays many of the properties associated with breast cancer, and the gland is hence susceptible for tumor formation. One factor that plays a crucial role in suppressing the development of tumors is the tumor suppressor p53. The importance of p53 in breast epithelium is evident from the high frequency of mutations and altered expression of the p53 gene in breast tumors (Coles et al., 1992; Wiseman and Werb, 2002) . It has been shown that full-term pregnancy early in reproductive life is protective against breast cancer, and p53 is thought to be a potential mediator (Sivaraman et al., 2001) . Since p53 plays a crucial role for the fate of a cell and is important in determining the fine balance between growth, differentiation, and cell death, both the expression and activity must be kept under tight control. It is regulated to a large extent by post-transcriptional and posttranslational mechanisms such as efficiency of translation, stability, and by degradation by ubiquitinmediated proteolysis. There are also clear evidences that regulation of p53 at the transcriptional level contributes significantly for controlling cellular p53 levels, and thereby the cell fate, in both normal and tumor cells (Sun et al., 1995; Balint and Reisman, 1996; Hellin et al., 1998; Kirch et al., 1999; Hale et al., 2000) . Therefore, identifying the factors that tightly control p53 gene expression in mammary epithelial cells is of importance to enhance our understanding of breast cancer.
The promoters of the mouse, rat, and human p53 genes are highly homologous, and many of the transcription factor elements are well conserved. Among these is a binding site for the nuclear factor 1 (NF1) transcription factor family. The NF1 family in vertebrates is composed of four members: NF1-A, NF1-B, NF1-C, and NF1-X. Transcripts of each NF1 gene are differentially spliced, yielding as many as nine distinct proteins from a single gene. The four NF1 members are expressed in unique but overlapping patterns, and have been shown to regulate both ubiquitous and tissuespecific genes (reviewed in Gronostajski (2000) ). Previously, NF1 proteins have been shown to contribute to the activation of the human p53 gene in HeLa cells (Furlong et al., 1996; Kirch et al., 1999) . However, it is clear that NF1 proteins do not regulate the p53 promoter in every tissue, since Furlong et al. (1996) reported an occupancy of NF1 proteins to the NF1-binding site in the p53 promoter with extracts from liver and prostate, but not from testis and spleen. Hitherto, the involvement of NF1 proteins in the regulation of p53 transcription in the mammary gland has never been demonstrated. Neither has its involvement in the p53 promoter activation in mouse been shown, and no specific NF1 isoform important for p53 gene activation has been identified.
Previously, little information existed concerning the expression pattern of the p53 gene during development, especially during pregnancy, of the mouse mammary gland (Strange et al., 1992; Kuperwasser et al., 2000) . Here we report that the p53 mRNA levels are increased at midpregnancy. We show by in vivo methods that this increase depends on binding of the transcription factor NF1-C2 to the mouse p53 promoter in mammary epithelial cells, leading to transcriptional activation. In a recent paper, we showed that during the development of the mouse mammary gland, the isoform NF1-C2 activates the carboxyl ester lipase (CEL) and whey acidic protein (WAP) gene promoters at midpregnancy, in concordance with the induction of these milk genes (Kannius-Janson et al., 2002) . Our present findings give further support for the role of NF1-C2 proteins in the control of genes induced or upregulated at midpregnancy, and indicate a broader role for NF1-C2 in the mammary gland besides milk gene activation.
Results
Binding of NF1 is important for high-level expression of the p53 gene in mouse mammary gland epithelial cells There are clear evidences that the steady-state level of p53 mRNA is lower in many breast tumors (Raman et al., 2000) . Thus, identifying transcription factors important for the regulation of the p53 gene is of importance for the understanding of breast tumor biology. It has been shown previously that occupancy of the NF1-binding site in the human p53 promoter is important for high-level expression of the human p53 gene in HeLa cells (Kirch et al., 1999) . However, the specific NF1 isoform involved was not identified. Since the NF1-binding site is conserved in the human, rat, and mouse p53 promoters, we examined if the NF1-binding site in the mouse p53 promoter is required for p53 gene activation in the mammary gland. A mutation in the NF1-binding site ( Figure 1a ) was introduced into a Luciferase construct containing the mouse p53 promoter from À441 to À100 (numbering is relative to the last base pair of exon 1 (Bienz-Tadmor et al., 1985) ). The functional activities of the wild-type and the mutant constructs were examined in the mouse mammary gland epithelial cell line HC11. As can be seen in Figure 1a , mutation of the NF1-binding site resulted in a drastic reduction of the p53 gene expression to less than 30%. Hence, this site contributes to high-level expression of the mouse p53 gene in mammary gland epithelial cells.
To show that the introduced mutation prevents binding of NF1 to the site, an EMSA was performed. Nuclear extracts from HC11 cells were incubated with an end-labeled double-stranded oligonucleotide containing the intact NF1-binding site and an excess of different competitors. The ability of the NF1-binding site in the adenovirus replication origin (adeno-NF1) to compete with the binding to the p53-NF1-binding site demonstrates that NF1 proteins are involved in the interaction with the p53 promoter ( Figure 1b) . A competitor with a mutated NF1-binding site (p53-NF1mut) was unable to compete the binding. Furthermore, NF1 proteins were unable to bind to a labeled oligonucleotide containing the mutated NF1-binding site (Figure 1b) .
The expression patterns of two different NF1 proteins, NF1-A1 and NF1-C2, differ during mouse mammary gland development at pregnancy
The particular NF1 isoforms involved in different processes have generally not been characterized, mainly due to the lack of specific antibodies. However, since antibodies directed against NF1-A and NF1-C are available today, we can and should begin to characterize specific isoforms of this versatile family. Earlier reports have revealed that all NF1 family members (NF1-A, NF1-B, NF1-C, and NF1-X) are expressed at the mRNA level in the mammary gland during pregnancy and lactation (Mukhopadhyay et al., 2001; KanniusJanson et al., 2002) . However, in a recent paper we have shown that the amount of NF1-C proteins in mammary epithelial cells is not mainly regulated at the transcriptional level, since we found high levels of NF1-C transcripts also at stages where we barely detected any NF1-C proteins (Kannius-Janson et al., 2002) . In the same paper, we showed that the only NF1-C isoform detected in the mouse mammary gland as well as in HC11 cells is a B50 kDa NF1-C2 protein (KanniusJanson et al., 2002) . Further, we showed that the existence of NF1-C2 protein varies during mouse mammary gland development at pregnancy. The NF1-C2 protein was strongly induced at day 13 of pregnancy, and was maintained until early lactation. Owing to the availability of the antibody directed against NF1-A, we were interested in investigating the expression pattern of NF1-A proteins in the mammary gland. We first verified by Western blot analysis whether this antibody is specific to NF1-A proteins, since this has never previously been demonstrated (Figure 2a ). We next investigated by Western blot analysis the expression pattern of NF1-A proteins in the mammary gland, and compared it with the pattern of NF1-C proteins. The analysis showed that a B60 kDa NF1-A protein is present throughout pregnancy and early lactation, and the levels do not significantly change (Figure 2b ), which is in contrast to the pattern observed for NF1-C2. An EMSA with an oligonucleotide representing nt À95 to À66 of the human CEL gene promoter (Lidberg et al., 1992) confirmed that the extracts were equally quantified. The same NF1-A protein as present in the glands is also present in the HC11 cells. We next investigated which NF1-A isoform this B60 kDa protein represents through RT-PCR, using primers with which we could detect and distinguish the different NF1-A isoforms that are known to exist in mouse (Kane et al., 2000; Mukhopadhyay et al., 2001 ).
PolyA
þ RNA from day 13 of pregnancy (P13) and from HC11 cells was isolated and subjected to RT-PCR. Three NF1-A products were detected corresponding to the isoforms NF1-A1, NF1-A2 (exon 7 spliced), and NF1-A4 (exon 10 spliced) (Figure 2c ). Subcloning and sequencing verified the identity of the NF1-A transcripts. Since the NF1-A2 and NF-A4 transcripts were barely detectable, we concluded that the B60 kDa protein is NF1-A1. Western blot with nuclear extracts from HC11 cells transfected with the pCHNF1A1.1, pCHNF1B2, pCHNF1C2, and pCHNF1 Â 2 expression plasmids. The extracts were run on a 10% SDS-polyacrylamide electrophoresis gel, and blotted onto a Hybond-P filter. The filter was incubated with anti-HA antibody, and then stripped and reincubated with the anti-NF1-A antibody as indicated. Note that the same filter was previously used when demonstrating the specificity of the NF1-C specific antibody (Kannius-Janson et al., 2002) . (b) Left panel: Nuclear extracts from HC11 cells and from mammary glands at different stages of development (days 10, 13, 16 of pregnancy (P10, P13, P16) and day 1 of lactation (L1)) were run on a 10% SDS-polyacrylamide electrophoresis gel, and blotted to a Hybond-P filter. The filter was incubated with an NF1-C-specific antibody (Kannius-Janson et al., 2002) , and then stripped and reincubated with an anti-NF1-A antibody. Right panel: As a control for equal quantification of the extracts, EMSA was performed with an oligonucleotide (unrelated-1) representing the human CEL gene promoter from nt À95 to À66. (c) PolyA þ RNA from day 13 of pregnancy (P13) and HC11 cells was subjected to RT-PCR with NF1-A-specific primers. The sizes of the amplified NF1-A fragments were 699, 607, and 572 bp, corresponding to the NF1-A1, NF1-A4, and NF1-A2 cDNAs, respectively In summary, we show that NF1-A1 and NF1-C2 proteins are present in the mammary gland during development, but the regulation of these two NF1 family members differs. NF1-A1 proteins exist during all stages of mammary gland development at pregnancy, whereas NF1-C2 proteins appear at midpregnancy.
NF1-C2 is the specific isoform responsible for p53 promoter activation in the mouse mammary gland
To determine whether any of the two NF1 proteins NF1-A1 or NF1-C2 interacts with the NF1-binding site in the mouse p53 promoter, an EMSA was performed. The nuclear extract from HC11 cells was incubated with an end-labeled double-stranded oligonucleotide containing the NF1-binding site (Figure 3 ). This analysis revealed that NF1-C is involved in the interaction, since the NF1-C specific antibody supershifted the complex. No supershifted band was observed with the NF1-A specific antibody or an antibody directed against Stat 5a. A similar NF1-C complex was also obtained when incubating the same oligonucleotide with extracts from mouse mammary glands at P13, in agreement with the induction of the NF1-C protein at this stage of development. Since we have shown that the only detected NF1-C protein in the mammary gland during development is the isoform NF1-C2, we can conclude that the NF1-C protein binding to the p53 promoter is NF1-C2. Recently, we have shown that during the development of the mouse mammary gland, NF1-C2 also activates the CEL and WAP genes at midpregnancy, in concordance with the induction of these milk genes (Kannius-Janson et al., 2002) . In this present study, we investigated if the NF1-C2 complex binding to the p53 gene promoter is similar to the one binding to the milk gene promoters. EMSA analysis with the oligonucleotide containing the NF1-binding site in the CEL gene promoter was performed, and showed that the same complex is involved in the regulation of all these genes (Figure 3 ). Taken together, we demonstrate that NF1-C2, but not NF1-A1, binds to and transcriptionally activates the p53 promoter. This suggests a broader role for NF1-C2 in the mammary gland at midpregnancy, beyond its induction of milk protein genes.
NF1-C2 has higher affinity than NF1-A1 to the NF1-binding site in the mouse p53 promoter
The EMSA analysis with the NF1-binding site in the p53 gene promoter revealed that although both NF1-A1 and NF1-C2 proteins are present in the extract, only NF1-C2 interacts with the site. Earlier, it was believed that all NF1 proteins bind to a given DNA-binding site with apparently similar affinities (Goyal et al., 1990; Kruse and Sippel, 1994) , but the emerging view is that the affinity can differ. For example, Osada et al. (1999) have shown that different NF1 proteins bind with different affinities to the NF1-binding site in the adenovirus replication origin. We gave further support to this in our previous publication, in which we showed that NF1-C2 had higher affinity than NF1-A1 to the NF1-binding site in the CEL gene promoter (KanniusJanson et al., 2002) . To investigate if this is the case also for the NF1-binding site in the p53 promoter, we overexpressed the NF1-C2 or NF1-A1 proteins in HC11 cells, prepared nuclear extracts, and investigated DNA binding with EMSA ( Figure 4 ). When overexpressing NF1-A1, a new weak and more slowly migrating band appeared, but the endogenous NF1-C2 complex remained at the same intensity. In contrast, when overexpressing NF1-C2, the new band that appeared had strong intensity, while the endogenous band was almost outcompeted. EMSA with an unrelated oligonucleotide confirmed that the different extracts were equally quantified and a Western blot analysis revealed that the recombinant NF1-A1 and NF1-C2 proteins were equally expressed. In conclusion, our data show that NF1-C2 binds to the p53 gene promoter with comparatively higher affinity than that of NF1-A1. Hence, different NF1 isoforms can bind to DNA with different affinities, which is in concordance with earlier findings (Osada et al., 1999; Kannius-Janson et al., 2002) .
The expression of the mouse p53 gene during mammary gland development peaks at midpregnancy
We have shown that the NF1-C2 protein, important for high-level p53 gene expression in vitro, is strongly upregulated at the protein level in the mammary gland at midpregnancy. This suggests that if NF1-C2 is important for the expression of the p53 gene in vivo, the p53 mRNA level will be upregulated at midpregnancy. To investigate the developmentally regulated expression, we assayed the steady-state levels of p53 mRNA at the virgin stage, days 10, 13, and 16 of pregnancy, day 1 of lactation, and 2 days after weaning by RT-PCR. Indeed, this analysis revealed that p53 gene expression is increased in the mammary gland at midpregnancy (Figure 5 ), and also indicates that the p53 gene is transcriptionally regulated during mouse mammary gland development. Taken together, our presented data support the conclusion that there is a connection between induction, or upregulation, of genes during midpregnancy and the differentiation-related binding of NF1-C2.
NF1-C2 occupies the mouse p53 promoter in vivo
To demonstrate that NF1-C2 occupies the mouse p53 promoter in vivo, a chromatin immunoprecipitation analysis in HC11 cells was performed. Two different NF1 antibodies (one recognizing all the four NF1 family members and one specific for NF1-C) were used, and the precipitated sequences were analysed by PCR. Figure 6a demonstrates that both NF1 antibodies precipitated a complex binding to the NF1-binding site (lanes 4 and 5), whereas an unrelated antibody did not (lane 6). To control for unspecific precipitation by the different antibodies, an unrelated region of the genome that lacks (Figure 6b) . No product was detected in this control amplification. We could therefore conclude that NF1, specifically NF1-C2, indeed occupies the p53 promoter in vivo.
NF1-C2 oligonucleotide decoys repress p53 gene expression in mammary gland epithelial cells
A powerful tool for studying gene regulation is the oligonucleotide decoy approach. The approach involves flooding the cell with competing synthetic transcription factor-binding sequences. If delivered into the cell in sufficient concentrations, these decoys have the potential to attenuate the binding of the transcription factor to promoter regions of target genes, and hence attenuate its ability to regulate the expression of these genes (Morishita et al., 1995 (Morishita et al., , 1997 Rafty et al., 2002) . We used the oligonucleotide decoy approach to investigate whether the CEL-NF1 oligonucleotide, highly specific for NF1-C2 in mouse mammary epithelial cells (Kannius-Janson et al., 2002), could repress p53 promoter activity in vivo. The CEL-NF1 oligonucleotide was transfected into HC11 cells and the endogenous p53 expression was analysed by RT-PCR. This analysis revealed that the p53 transcription was decreased in cells transfected with the CEL-NF1 oligonucleotide (Figure 7) . In contrast, p53 promoter activity was not affected by an identical concentration of CEL-NF1mut oligonucleotide, in which the NF1-C2-binding site was mutated (Figure 7 ). Transfection with a small fraction of radioactively labeled oligonucleotides enabled us to ensure that both oligonucleotides entered the cells with similar efficiencies. The decoy study demonstrates the capacity of the NF1-C2-specific oligonucleotide to antagonize the activity of p53 transcription, and also gives further evidence that NF1-C2 is important for high-level expression of the p53 gene in the mammary gland in vivo.
Discussion
The tumor suppressor p53 is important in determining the fine balance between growth, differentiation, and cell death, which are fundamental for the normal life of organisms. It serves an important role in protecting cells from DNA damage and preventing tumor formation, and mutations in the p53 gene are frequent in breast tumors (Coles et al., 1992) . The cellular effects of p53 activity might become very undesirable if the protein is wrongly activated and p53 must therefore be kept under tight control, being unleashed only when a cell accumulates lesions that may otherwise drive it into a cancerous state (Oren, 1999) . There are also clear evidences that regulation of the p53 gene at the transcriptional level contributes significantly for controlling cellular p53 levels (Soini et al., 1992; Balint and Reisman, 1996) . Thus, detailed information about the mechanism that regulates the p53 gene is highly important for the understanding of breast tumor biology.
In this paper, we show that the steady-state levels of p53 mRNA in the mouse mammary gland increase during pregnancy, with a peak at midpregnancy, decrease during lactation, and then again increase during involution. These data indicate that the mouse p53 gene is transcriptionally regulated during mammary development. Previously, NF1 proteins have been shown to contribute to the activation of the human p53 gene in HeLa cells (Furlong et al., 1996; Kirch et al., 1999) . The specific member of the NF1 transcription factor family involved was not characterized. Since we knew from our earlier report (Kannius-Janson et al., 2002) that the specific NF1 isoform, NF1-C2, activates milk genes induced at midpregnancy, we speculated that this isoform might have a broader role in the mammary gland and will be important not only for milk gene activation, but also for regulation of genes such as p53. We show that binding of NF1-C2 to the mouse p53 promoter at midpregnancy is indeed important for highlevel expression of the p53 gene in mammary epithelial cells. Mutation of the NF1-binding site resulted in a drastic reduction of the expression to less than 30%. By using chromatin immunoprecipitation, we verified that NF1-C2 proteins bind to the p53 promoter in vivo. Further, the oligonucleotide decoy approach allowed us to demonstrate the capacity of an oligonucleotide previously shown to be highly specific for NF1-C2 (Kannius-Janson et al., 2002) to antagonize the activity of p53 transcription. These data gives further evidence for the importance of NF1-C2 in high-level expression of the p53 gene in vivo in the mammary gland during pregnancy. This is the first time that NF1 proteins are shown to regulate the p53 gene in mouse, as well as in the mammary gland, and we also demonstrate which specific NF1-isoform, NF1-C2, that is involved in p53 activation.
Transcripts from all the four NF1 genes are found in the mouse mammary gland (Mukhopadhyay et al., 2001; Kannius-Janson et al., 2002) . However, we have shown earlier that the existence of NF1 transcripts does not necessarily bring about the existence of the corresponding NF1 protein products (Kannius-Janson et al., 2002) . The only NF1 isoform identified so far in the mammary gland at the protein level is NF1-C2 (Kannius-Janson et al., 2002) . We now extend this information by showing that a B60 kDa NF1-A protein, identified as NF1-A1, is also present in the mammary gland. However, this protein is not involved in p53 gene activation, which is demonstrated by the inability of an NF1-A specific antibody to supershift the DNA-binding complex in EMSA analysis. We further demonstrate, in overexpression experiments, that the lack of NF1-A binding is due to the fact that NF1-C2 has higher affinity than NF1-A1 to the NF1-binding site in the p53 promoter. The NF1-A1 proteins exist during all stages of mammary gland development at pregnancy, while NF1-C2 proteins are induced at midpregnancy (Kannius-Janson et al., 2002) , which suggests that NF1-C2 might indeed have a more important role for mammary gland development at midpregnancy.
The reason for the upregulation of the p53 gene expression in the mammary gland at midpregnancy is currently not clear. However, at this stage the mammary epithelial cells undergo extensive proliferation, and are therefore at high risk of accumulating DNA damages. Possibly, an induction of higher p53 mRNA levels places the cells in a state of anticipation. As long as there is no DNA damage or other stress, p53 remains latent and does not interfere with normal cellular transactions. However, if conditions emerge that call for a p53 response, the presence of higher levels of p53 mRNA ensures that such response will be rapid and effective. Apart from its role in apoptosis and cell cycle regulation, p53 has also been shown to participate in the differentiation process of a number of cell types such as pancreatic carcinoma cells, muscle cells, keratinocytes, neurons, thyroid cells, various hematopoietic cell lines, and kidney cells (Shaulsky et al., 1991; Feinstein et al., 1992; Banerjee et al., 1995; Ehinger et al., 1995; Soddu et al., 1996; Almog and Rotter, 1997; Lang et al., 1998; Chylicki et al., 2000; Saifudeen et al., 2002) . Perhaps, p53 might have a similar role in the mammary gland during midpregnancy, since this is the stage when the terminal differentiation of the epithelium begins.
The steady-state level of p53 mRNA has been shown to be lower in many breast cancers than in the normal breast epithelium (Raman et al., 2000) . Since we demonstrate the importance of NF1-C2 in high-level p53 gene expression in mammary tissue, the reduced p53 mRNA levels in breast tumors could be a consequence of lower levels of NF1-C2 proteins in these tumors. Indeed, depletion of NF1 proteins has been observed in many breast tumors (Nayak and Das, 1999) . There are indications that NF1-C2 might influence specific pathways of oncogenic transformation. For example, transformation of the mammary epithelium with Ha-ras and c-myc inhibited the differentiation of the mammary gland and milk protein gene expression (Andres et al., 1988) . Further, overexpression of Ha-ras was shown to downregulate NF1-C in mouse mammary epithelial cells on the level of mRNA stability and DNA-binding activity (Nebl et al., 1994) . Since we have shown that NF1-C2 is the only NF1-C protein in the mouse mammary gland, we conclude that this isoform is the one that Ha-ras downregulates in this tissue. Further, overexpression of c-myc in transgenic mice suppressed the expression of the milk gene WAP (Andres et al., 1988) . It has been shown earlier, in other tissues, that cmyc overexpression leads to less active NF1 proteins (Yang et al., 1993) . Therefore, since we have demonstrated that the WAP gene is regulated by NF1-C2, the mechanism by which c-myc suppresses WAP gene expression could be by inactivating NF1-C2. Taken together, we can conclude that NF1-C2 can activate the p53 tumor suppressor gene, and that it can be downregulated by oncogenes such as c-myc and Ha-ras. Thus, these listed examples suggest that the loss of NF1-C2 protein function could influence the progression towards neoplastic transformation and the development of tumors. We therefore propose that NF1-C2 itself might represent a tumor suppressor.
Materials and methods

Cell cultures
The mouse mammary epithelial cell line HC11, kindly provided by Dr R Ball, Friedrich Miescher-Institute, Basel, was grown at 371C in a 5% CO 2 /95% air atmosphere in RPMI 1640 medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, 5 mg/ml insulin, and 10 ng/ml EGF.
Reporter gene constructs
A 342-bp DNA fragment representing nucleotides À441 to À100 (with respect to the last base pair of exon 1 (BienzTadmor et al., 1985) ) of the mouse p53 promoter was amplified from genomic mouse DNA by PCR with the primers 5 0 -GGTCCACTTACGATAAAAAC-3 0 and 5 0 -GGTCCCAAT-GAACTGAAGCT-3 0 . The product was cloned into the pGL2-basic vector (Promega) with a modified polylinker , upstream of the luciferase reporter gene, creating the 'mouse-p53-Luc' construct. Mutation in the NF1 site was made by the Stratagene Quickchange site-directed mutagenesis kit, and the mutated promoter was cloned into the modified pGL2-basic vector, creating the 'mouse-p53-NF1mut-Luc' construct.
Transient transfection and reporter gene assay HC11 cells were transiently transfected using lipofectin in Optimem (Life Technologies), with 5 mg of the mouse-p53-Luc construct or the mouse-p53-NF1mut-Luc construct, together with 0.5 mg of the pCMV-b-galactosidase reporter plasmid. After 24 h, the medium was switched to the RPMI 1640 medium, supplemented as described above. The transfected cells were harvested after 40 h of transfection as described previously . Luciferase assays were performed using the Promega kit with 50 ml of cell lysate, and assayed in a luminometer (Berthold). The luciferase activity was normalized to the luminescent b-galactosidase activity, determined by the Clontech protocol for b-galactosidase assay.
Nuclear protein preparation
The inguinal mammary glands from different stages of development were dissected from F1: C57Bl6 Â CBA mice. Preparations of nuclear extracts from these glands, and from HC11 cells, were carried out as described previously (Ausubel et al., 1987) . Protein concentrations of the extracts were determined by the method of Bradford (Bradford, 1976) and the extracts were stored in aliquots at À701C before use.
Electrophoretic mobility shift assay (EMSA)
The radioactively labeled oligonucleotides used in the EMSAs were created by annealing of complementary oligonucleotides and filling in with Klenow polymerase in the presence of (a-32 P)-dCTP. The sequences of the labeled and unlabeled oligonucleotides were as follows (only upper strands are shown): 5 0 -CTTGTTATGGCGACTATCCAGCTTTGTG-3 0 (p53-NF1, representing À219 to À192 of the mouse p53 promoter with respect to the last base pair of exon 1, BienzTadmor et al., 1985) , 5 0 -CTTGTTATATAGACTATCCAGC TTTGTG-3 0 (p53-NF1mut), 5 0 -CTAGCTATTTTGGATTG AAGCCAATATG-3 0 (adeno-NF1), and 5 0 -CTGAGGGGG TAGAGGGGAGGGAGTGCCTGA-3 0 (unrelated-1, representing the human CEL gene promoter from À95 to À66, Lidberg et al., 1992) , used in Figure 1b, 2b) , and 5 0 -TCTG TCCCAGAAGTCACGTGCTCGG-3 0 (unrelated-2, an USF oligonucleotide (Bengtsson et al., 2002) , used in Figure 4) . The CEL-NF1 oligonucleotide was the same as the NF1 oligonucleotide described previously (Kannius-Janson et al., 2002) . Nuclear extracts (8 mg) were incubated with 1.5 mg of poly(dIdC) and 25 000 c.p.m. of labeled probe in EMSA-binding buffer (20 mm HEPES, pH 7.9, 50 mm KCl, 10% glycerol, 2 mm MgCl 2 , 0.5 mm EDTA, 0.1 mg/ml BSA, 0.5 mm dithiothreitol) in a 20 ml reaction volume, for 15 min at room temperature. For supershift experiments, 2 ml of anti-NF1-C antibody (rabbit polyclonal antiserum, 8199, reacting with the C-terminal half of NF1-C, kindly provided by Dr N Tanese, NYU Medical Center, NY, USA), previously shown to be NF1-C specific (Kannius-Janson et al., 2002) , 0.5 ml of Nushiftt anti-NF1-A antibody (Geneka) or 2 ml of anti-Stat 5a antibody (Santa Cruz) was included in the binding reaction and preincubated for 15 min before addition of probe. DNAprotein complexes were resolved on a 6% polyacrylamide gel (tris/glycine, 5% glycerol).
Overexpression of NF1 proteins in HC11 cells
HC11 cells were transiently transfected using lipofectin in Optimem (Life Technologies), with 5 mg of either of the pCHNF1A1.1, pCHNF1B2, pCHNF1C2 or pCHNF1 Â 2 expression plasmids (expressing HA-tagged (hemagglutinin) mouse NF1-A1, NF1-B2, NF1-C2, and NF1-X2, kindly provided by Dr RM Gronostajski, Lerner Institute, OH, USA (Gronostajski, 2000) ) per 6-cm culture dish. After 24 h, the medium was switched to the RPMI 1640 medium, supplemented as described above. After about 40 h, the cells were harvested and nuclear proteins were prepared.
Western blot analysis
Nuclear extracts (20 mg) were electrophoresed through a 10% SDS-polyacrylamide gel, followed by electroblotting onto Hybond-P filter (Amersham Phamacia Biotech). To detect endogenous NF1-C or NF1-A, the same filter was first incubated with a 1 : 1000 dilution of the anti-NF1-C antibody (8199), and then stripped and reincubated with a 1 : 2000 dilution of the Nushiftt anti-NF1-A antibody (Geneka). The primary antibodies were detected with POD-conjugated anti-rabbit IgG using the BM Chemiluminescence Blotting Substrate POD (Roche) and ECL films (Amersham Pharmacia Biotech). In the overexpression experiments, the overexpressed NF1 proteins were detected by incubating the filter with anti-HA antibody (Roche), and then stripped and reincubated with the anti-NF1-A antibody (Geneka). The filter is the same as the one used previously with the NF1-C specific antibody (8199) (Kannius-Janson et al., 2002) . The primary antibodies were detected with POD-conjugated antimouse or anti-rabbit IgG (Roche), respectively.
RNA analysis
The inguinal mammary glands from different stages of development were dissected from F1: C57Bl6 Â CBA mice. Total RNA was extracted from these glands, and from HC11 cells, by Trizol (Invitrogen) according to the manufacturer's instructions. PolyA þ RNA was purified using Oligotex mRNA kit (Qiagen). RT-PCR experiments were carried out using the Titant One-Tube RT-PCR System (Roche). The primers used for mouse p53 amplification were 5 0 -GGAGGAGTCACAGT CGGATATCAGC-3 0 and 5 0 -TCCTTCCACCCGGATAAGA TGCTGG-3 0 , yielding a 577-bp fragment. For mouse glyceraldehydes-3-phosphate dehydrogenase (GAPDH) amplification, the primers used were 5 0 -CACCACCATGGAGAA GGCCGGGGCC-3 0 and 5 0 -TTGAAGTCGCAGGAG ACA ACCTGGT-3 0 , yielding a 554-bp fragment. The primers used for mouse NF1-A amplification were 5 0 -GAGGATGAAATG GACAGTCCTGGTG-3 0 and 5 0 -GATGCTGCAACTTTTAT CCCA GGTACCAGG-3 0 , yielding a 699-bp fragment of the mouse NF1-A1 (GenBankt accession number NM010905), a 572-bp fragment of the mouse NF1-A2 (GenBankt accession number Y07691), and a 607-bp fragment of the mouse NF1-A4 (Mukhopadhyay et al., 2001) . For each reaction, 10 ng polyA þ RNA was used, and the reactions were incubated at 501C for 30 min, 971C for 2 min, followed by 10 cycles of 30 s at 971C, 30 s at 571C and 1 min at 681C, and 15 cycles (or 30 cycles for NF1-A) of 30 s at 971C, 30 s at 571C and 1 min at 681C. From cycle 11, the 681C step was extended by 5 s every cycle. Finally, the reactions were incubated at 681C for 7 min.
Chromatin immunoprecipitation analysis
Chromatin immunoprecipitaion was performed with the ChIP assay kit (Upstate Biotechnology) according to the manufacturer's instructions with a few changes. In each assay, 10 7 HC11 cells were used. Protein-DNA complexes were precipitated with 5 mg of an anti-NF1 antibody (Santa Cruz), 8 ml of the anti-NF1-C antibody (8199), or 5 mg of a anti-CEL antibody (referred to as unrelated antibody) (Stromqvist et al., 1997) . After the protein-DNA crosslinks in the precipitated complexes had been reversed with 20 ml of 5 m NaCl at 651C for 4 h, the DNA was purified with QiaQuick spin columns (Qiagen) and eluted in 50 ml per column 10 mm Tris, pH 8.0. DNA (2 ml) was used for PCR. The p53 promoter was amplified with the primers 5 0 -GGTCCACTTACGA-TAAAAAC-3 0 and 5 0 -GGTCCCAATGAACTGAAGCT-3 0 , yielding a 342-bp fragment of the mouse p53 promoter. The reactions were incubated at 951C for 5 min, followed by 35 cycles of 951C for 1 min, 56.51C for 1 min, and 721C for 1 min. To control for unspecific precipitation by the different antibodies, a region of mouse chromosome 4 that lacks an NF1-binding site was amplified with the primers 5 0 -CTAT-TACGTGGTTGTACAGATCAAG-3 0 and 5 0 -AGTGACAC TCACAGATTAGAGGG-3 0 , yielding a 542-bp fragment. The reactions were incubated at 961C for 2 min, followed by 35 cycles of 941C for 30 s, 631C for 30 s, and 721C for 1 min. Finally, the reactions were incubated at 721C for 4 min.
Oligonucleotide decoy analysis
Unlabeled double-stranded CEL-NF1 oligonucleotide or CEL-NF1mut oligonucleotide (1 mm; Kannius-Janson et al., 1998) was transfected into HC11 cells plated to B50% confluence in six-hole plates with 4 ml of oligofectamin (Invitrogen) per hole, according to the manufacturer's instructions. After 48 h, the cells were harvested and RNA was purified with Trizol (Invitrogen) according to the manufacturer's instructions. Endogenous mouse p53 and mouse GAPDH transcripts were amplified as described in the section RNA analysis. To ensure that both oligonucleotides entered the cells with similar efficiency, a small fraction of the oligonucleotides was radioactively labeled (250 fmol, 250 000 c.p.m.) and transfected together with the bulk of unlabeled oligonucleotides. After 48 h transfection, the cells were harvested and lysed with 750 ml per hole of lysis buffer (20 mm Tris pH 7.5, 100 mm NaCl, 1% Triton X-100, 0.5 mm EDTA), and radioactivity in the cells was assessed in an automatic scintillation counter (Beckman). The c.p.m. values were normalized to the protein concentration of each sample, determined by the DC Protein Assay kit (Bio-Rad). The transfection with radioactive oligonucleotides was performed three independent times, and each time the two oligonucleotides were transfected in triplicates.
